Cartilage Injury

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

MEDIPOST
MEDIPOSTKorea - Gyeonggi
1 program
1
CartistemPhase 31 trial
Active Trials
NCT01041001CompletedEst. Jan 2011
Geistlich Pharma
Geistlich PharmaSwitzerland - Root
1 program
1
MicrofracturePhase 31 trial
Active Trials
NCT02993510Completed67Est. Jul 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MEDIPOSTCartistem
Geistlich PharmaMicrofracture

Clinical Trials (2)

Total enrollment: 67 patients across 2 trials

Study to Compare Efficacy and Safety of Cartistem and Microfracture in Patients With Knee Articular Cartilage Injury

Start: Feb 2009Est. completion: Jan 2011
Phase 3Completed

A Randomized Controlled Trial Comparing Chondro-Gide® to Microfracture Alone for Treatment of Knee Cartilage Defects.

Start: Dec 2003Est. completion: Jul 201667 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space